163 related articles for article (PubMed ID: 8206967)
1. Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan.
Ji H; Leung M; Zhang Y; Catt KJ; Sandberg K
J Biol Chem; 1994 Jun; 269(24):16533-6. PubMed ID: 8206967
[TBL] [Abstract][Full Text] [Related]
2. Genetic transfer of a nonpeptide antagonist binding site to a previously unresponsive angiotensin receptor.
Ji H; Zheng W; Zhang Y; Catt KJ; Sandberg K
Proc Natl Acad Sci U S A; 1995 Sep; 92(20):9240-4. PubMed ID: 7568109
[TBL] [Abstract][Full Text] [Related]
3. Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor.
Perlman S; Schambye HT; Rivero RA; Greenlee WJ; Hjorth SA; Schwartz TW
J Biol Chem; 1995 Jan; 270(4):1493-6. PubMed ID: 7829475
[TBL] [Abstract][Full Text] [Related]
4. Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding and coupling. Reconstitution of the binding site by co-expression of two deficient mutants.
Monnot C; Bihoreau C; Conchon S; Curnow KM; Corvol P; Clauser E
J Biol Chem; 1996 Jan; 271(3):1507-13. PubMed ID: 8576145
[TBL] [Abstract][Full Text] [Related]
5. Identification of nonconserved amino acids in the AT1 receptor which comprise a general binding site for biphenylimidazole antagonists.
Nirula V; Zheng W; Krishnamurthi K; Sandberg K
FEBS Lett; 1996 Oct; 394(3):361-4. PubMed ID: 8830675
[TBL] [Abstract][Full Text] [Related]
6. Binding of valsartan to mammalian angiotensin AT1 receptors.
de Gasparo M; Whitebread S
Regul Pept; 1995 Nov; 59(3):303-11. PubMed ID: 8577935
[TBL] [Abstract][Full Text] [Related]
7. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms.
Noda K; Saad Y; Kinoshita A; Boyle TP; Graham RM; Husain A; Karnik SS
J Biol Chem; 1995 Feb; 270(5):2284-9. PubMed ID: 7530721
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the binding of [3H]L-158,809: a new potent and selective nonpeptide angiotensin II receptor (AT1) antagonist radioligand.
Chen TB; Lotti VJ; Chang RS
Mol Pharmacol; 1992 Dec; 42(6):1077-82. PubMed ID: 1480133
[TBL] [Abstract][Full Text] [Related]
9. Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism.
Haddad G; Amiri F; Garcia R
Regul Pept; 1997 Jan; 68(2):111-7. PubMed ID: 9110382
[TBL] [Abstract][Full Text] [Related]
10. Interaction of biphenylimidazole and imidazoleacrylic acid nonpeptide antagonists with valine 108 in TM III of the AT1 angiotensin receptor.
Nirula V; Zheng W; Sothinathan R; Sandberg K
Br J Pharmacol; 1996 Dec; 119(8):1505-7. PubMed ID: 8982494
[TBL] [Abstract][Full Text] [Related]
11. Binding of [3H]angiotensin II and [3H]DuP 753 (Losartan) to rat liver homogenates reveals multiple sites. Relationship to AT1a- and AT1b-type angiotensin receptors and novel nonangiotensin binding sites.
Widdowson PS; Renouard A; Vilaine JP
Peptides; 1993; 14(4):829-37. PubMed ID: 8234032
[TBL] [Abstract][Full Text] [Related]
12. Amino acids of the third transmembrane domain of the AT1A angiotensin II receptor are involved in the differential recognition of peptide and nonpeptide ligands.
Groblewski T; Maigret B; Nouet S; Larguier R; Lombard C; Bonnafous JC; Marie J
Biochem Biophys Res Commun; 1995 Apr; 209(1):153-60. PubMed ID: 7726829
[TBL] [Abstract][Full Text] [Related]
13. Modulation of angiotensin II binding affinity by allosteric interaction of polyvinyl sulfate with an intracellular domain of the DuP-753-sensitive angiotensin II receptor of bovine adrenal glomerulosa.
Boulay G; Servant G; Luong TT; Escher E; Guillemette G
Mol Pharmacol; 1992 Apr; 41(4):809-15. PubMed ID: 1569928
[TBL] [Abstract][Full Text] [Related]
14. Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist.
Lee SH; Jung YS; Lee BH; Yun SI; Yoo SE; Shin HS
J Cardiovasc Pharmacol; 1999 Mar; 33(3):367-74. PubMed ID: 10069670
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation.
Virone-Oddos A; Desangle V; Provost D; Cazes M; Caussade F; Cloarec A
Br J Pharmacol; 1997 Feb; 120(3):488-94. PubMed ID: 9031754
[TBL] [Abstract][Full Text] [Related]
16. Disulfide bridges in extracellular domains of angiotensin II receptor type IA.
Ohyama K; Yamano Y; Sano T; Nakagomi Y; Hamakubo T; Morishima I; Inagami T
Regul Pept; 1995 May; 57(2):141-7. PubMed ID: 7659790
[TBL] [Abstract][Full Text] [Related]
17. Human angiotensin receptor subtypes.
Smith RD; Timmermans PB
Curr Opin Nephrol Hypertens; 1994 Jan; 3(1):112-22. PubMed ID: 7850406
[TBL] [Abstract][Full Text] [Related]
18. Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors.
Schambye HT; Hjorth SA; Bergsma DJ; Sathe G; Schwartz TW
Proc Natl Acad Sci U S A; 1994 Jul; 91(15):7046-50. PubMed ID: 8041743
[TBL] [Abstract][Full Text] [Related]
19. Interactions of nonpeptide angiotensin II receptor antagonists at imidazoline/guanidinium receptor sites in rat forebrain.
Li Z; Bosch SM; Smith TL; Diz DI
J Cardiovasc Pharmacol; 1996 Sep; 28(3):425-31. PubMed ID: 8877590
[TBL] [Abstract][Full Text] [Related]
20. A computer modeling postulated mechanism for angiotensin II receptor activation.
Joseph MP; Maigret B; Bonnafous JC; Marie J; Scheraga HA
J Protein Chem; 1995 Jul; 14(5):381-98. PubMed ID: 8590606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
